Despite advancements in treatments, including proteasome inhibitors, immunomodulatory drugs, CD38-targeting monoclonal antibodies, and more recently, B-cell maturation antigen (BCMA)-targeting CAR-T cells, MM remains largely incurable, with most patients eventually experiencing relapse (10, 11). Here, TNFRSF17 is linked to Miyoshi myopathy.